Moderna (MRNA) Stock Falls 9% After FDA Rejects Flu Vaccine Application

TLDR Moderna (MRNA) stock plummeted 9% in premarket and 14% in Frankfurt after FDA rejected flu vaccine application FDA refused to review mRNA-1010 due to trial design concerns, not safety or efficacy issues Agency objected to Moderna using standard flu shot as comparator instead of “best available care” Trial with 40,000+ participants showed vaccine was [...]

The post Moderna (MRNA) Stock Falls 9% After FDA Rejects Flu Vaccine Application appeared first on Blockonomi.